Novo Nordisk to cap insulin prices in Minnesota settlement
NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was harshly criticized by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure to properly disclose payments to health and ...
Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...
ST. PAUL, Minn. – Minnesota Attorney General Keith Ellison settled with insulin manufacturers Eli Lilly, Sanofi, and Novo ...
Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news ...
Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback